A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations | NYU Langone Health

Go Back to All Clinical Trials

A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Myelodysplastic Syndrome
Age: Between 18 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:

1. Histologically confirmed Myelodysplastic Syndrome with positive TET2 mutations 2. Myeloblasts account for less than 20% of leukocytes on peripheral blood and bone marrow aspirate 3. Adequate organ function

You may not be eligible for this study if the following are true:

1. Any cancer-related therapy for the current disease within 2 weeks of screening 2. Requirement for systemic immunosuppressive therapy 3. Uncontrolled concurrent serious illness